Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03321604 · ClinicalTrials.gov registry record
Kidney Information Network for Disease Research and Education
A clinical trial, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- 338
- Enrollment target
NCT03321604: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT03321604 is a clinical trial that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 338 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03321604 was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- 338 participants
- Enrollment target
Study Summary
In this study, Investigators will conduct a prospective cohort study of dialysis patients by collecting research-quality information on patient characteristics, comorbid diseases and laboratory markers used in routine practice, as well as novel biochemical markers and genetic data. Investigators will utilize data from the cohort to test the independent relationship between biochemical and genetic markers and Fabry disease and other rare diseases.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2019-11-21 |
Why NCT03321604 stopped before completion
NCT03321604 is an observational study that tracks outcomes without assigning an intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03321604 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03321604 about?
NCT03321604 is a clinical study titled "Kidney Information Network for Disease Research and Education". In this study, Investigators will conduct a prospective cohort study of dialysis patients by collecting research-quality information on patient characteristics, comorbid diseases and laboratory markers used in routine practice, as well as novel biochemical markers and genetic data. Investigators wil...
What is the current status of trial NCT03321604?
This trial is currently terminated. The enrollment target is 338 participants. The study started on 2018-01-01. Estimated completion is 2019-11-21.
Who is sponsoring clinical trial NCT03321604?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI